Drug Profile
CX 1739
Alternative Names: CX-1739Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Cortex Pharmaceuticals
- Developer Cortex Pharmaceuticals; National Institute of Drug Abuse; RespireRx Pharmaceuticals
- Class Antidementias; Mood stabilisers; Respiratory stimulants
- Mechanism of Action AMPA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Respiratory insufficiency; Sleep apnoea syndrome
- Preclinical Spinal cord injuries
- Discontinued Attention-deficit hyperactivity disorder; Substance-related disorders